Abstract
Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. Our aim was to investigate the role of plasma OPN and its gene polymorphism at nt - 443 in response to PEG IFN in Saudi patients with chronic HCV. Blood was collected from 87 patients with chronic hepatitis C before treatment, then patients received PEG IFN α2b plus ribavirin combination therapy. Another 25 healthy subjects, matched for age and sex to patients, were enrolled as controls. Single nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood level were analyzed. The frequency of patients who reached sustained virological response (SVR) was increased in patients with T/T at nt - 443 than in those with C/C or C/T. Also the frequency of T allele was increased in responders than in non-responders. However, this increase was not statistically significant. The blood level of OPN was significantly increased in non-responders (Mean±SD=37.21±3.9) in comparison to responders (Mean±SD=33.22±4.1). Osteopontin blood level can be considered as a reliable predictor to PEG IFN α2b plus ribavirin therapy in chronic HCV Saudi Patients.
Highlights
Infection with hepatitis C virus (HCV) is a common global cause of chronic liver disease, which is true in Saudi Arabia
Patients that participated in the study fulfilled the following inclusion criteria: age 18–54 years, elevated alanine transaminase (ALT) and aspartate transaminase (AST); within 6 months prior to entry of the study, positive HCV antibodies, detectable HCV-RNA, HCV genotype 4, liver biopsy showing histological evidence of chronic hepatitis without cirrhosis or fibrosis, and they were never previously treated with IFN
The majority of HCV infected patients do not clear the virus and this leads to chronic hepatitis which may progresses to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)[4,5,11]
Summary
Infection with hepatitis C virus (HCV) is a common global cause of chronic liver disease, which is true in Saudi Arabia. Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim was to investigate the role of plasma OPN and its gene polymorphism at nt – 443 in response to PEG IFN in Saudi patients with chronic HCV. Methods: Blood was collected from 87 patients with chronic hepatitis C before treatment, patients received PEG IFN α2b plus ribavirin combination therapy. Another 25 healthy subjects, matched for age and sex to patients, were enrolled as controls. Conclusion: Osteopontin blood level can be considered as a reliable predictor to PEG IFN α2b plus ribavirin therapy in chronic HCV Saudi Patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
